Evidence map›Paper›PMID 41694381›Full record

ArticleFrontiers in immunology2026

Tumor-reactive TCRs within exhausted TILs reveal cancer type-specific immune landscapes in renal cell carcinoma.

Mitsuru Komahashi, Shun Horaguchi, Kayoko Tsuji, Daisuke Hoshino, Takeshi Kishida, Kimitsugu Usui, Noboru Nakaigawa, Shinya Sato, Hiroshi Hamana, Hiroyuki Kishi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mitsuru Komahashi *Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Shun Horaguchi *Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Kayoko Tsuji *Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Daisuke HoshinoCancer Biology Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Takeshi KishidaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Kimitsugu UsuiDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Noboru NakaigawaDepartment of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Shinya SatoMolecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Feifei WeiDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Yasunobu ManoDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Taku KouroDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Shuichiro UeharaDepartment of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan.
Tetsuro SasadaDivision of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) presents a unique immunological paradox: abundant CD8

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLymphocytes, Tumor-InfiltratingReceptors, Antigen, T-CellCD8-Positive T-LymphocytesFemaleGene Expression ProfilingHumansSingle-Cell AnalysisT-Cell ExhaustionTranscriptomeTumor MicroenvironmentReceptors, Antigen, T-Cellclear cell renal cell carcinomamachine-learningorganoidsingle-cell RNA sequencingT cell receptor (TCR)TCR-T cell therapytranscriptometumor-infiltrating lymphocytes

Identifiers

PMID41694381
PMCPMC12894369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.